BioCentury | Feb 25, 2021
Management Tracks

Promotions at Anokion and GlycoMimetics; Read to chair TriNetX and moves at Lava, PYC, Quotient, ImmunoSCAPE and Emergex

...CSO at ophthalmology companies Fortify Therapeutics and Retinagenix Therapeutics and head of translational medicine at Navire...
BioCentury | Feb 13, 2021
Product Development

Howdy partner: MD Anderson’s evolving industry collaboration strategy

...Science (IACS), three have found corporate partners in Artios Pharma Ltd., Ipsen Group (Euronext:IPN; Pink:IPSEY) and Navire Pharma Inc....
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

...financial terms for the four deals are undisclosed. The newco’s third asset is solid tumor candidate BBP-398. Navire Pharma Inc....
...focusing development of the SHP-2 inhibitor on drug-resistant tumors and other hard-to-treat cancers. Yu said Navire...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

...program BBP-398 from Navire Pharma Inc., another BridgeBio company. Navire...
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

...see “BridgeBio Gets Novartis’ FGFR Kinase Inhibitor”).The newco’s third asset is solid tumor candidate BBP-398. Navire Pharma Inc....
...focusing development of the SHP-2 inhibitor on drug-resistant tumors and other hard-to-treat cancers. Yu said Navire...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...Recursion Pharmaceuticals Inc. hired Shafique Virani as chief corporate development officer. He was CEO of Navire Pharma Inc....
BioCentury | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

...Oxford BioMedica plc (LSE:OXB). Virani was CEO-in-residence at BridgeBio Pharma Inc. (NASDAQ:BBIO) and CEO of Navire Pharma Inc....
BioCentury | Aug 17, 2018
Finance

MD Anderson’s blooms

...cited the 2017 launches of autophagy company Vescor LLC with Deerfield Management and cancer subsidiary Navire Pharma Inc....
...autophagy-targeted cancer, and the newco will own the rights to all developed candidates. With BridgeBio, Navire...
BioCentury | Nov 9, 2017
Finance

The return of big

...since the start of 4Q17. One was with BridgeBio Pharma LLC to create the JV Navire Pharma Inc....
...of Biomedical Innovation Health and Nutrition, Osaka, Japan National Institutes of Health (NIH), Bethesda, Md. Navire Pharma Inc....
BioCentury | Oct 6, 2017
Company News

BridgeBio launches SHP-2 inhibitor play Navire

...BridgeBio Pharma LLC (Palo Alto, Calif.) launched Navire Pharma Inc. , a subsidiary aimed at treating genetically driven...
...a subsidiary aimed at treating genetically driven, treatment-resistant cancer, with a $30 million investment. Navire...
...led by IACS' Phil Jones and New York University's Benjamin Neel discovered Navire's lead compounds. Navire’s...
Items per page:
1 - 10 of 11
BioCentury | Feb 25, 2021
Management Tracks

Promotions at Anokion and GlycoMimetics; Read to chair TriNetX and moves at Lava, PYC, Quotient, ImmunoSCAPE and Emergex

...CSO at ophthalmology companies Fortify Therapeutics and Retinagenix Therapeutics and head of translational medicine at Navire...
BioCentury | Feb 13, 2021
Product Development

Howdy partner: MD Anderson’s evolving industry collaboration strategy

...Science (IACS), three have found corporate partners in Artios Pharma Ltd., Ipsen Group (Euronext:IPN; Pink:IPSEY) and Navire Pharma Inc....
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

...financial terms for the four deals are undisclosed. The newco’s third asset is solid tumor candidate BBP-398. Navire Pharma Inc....
...focusing development of the SHP-2 inhibitor on drug-resistant tumors and other hard-to-treat cancers. Yu said Navire...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

...program BBP-398 from Navire Pharma Inc., another BridgeBio company. Navire...
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

...see “BridgeBio Gets Novartis’ FGFR Kinase Inhibitor”).The newco’s third asset is solid tumor candidate BBP-398. Navire Pharma Inc....
...focusing development of the SHP-2 inhibitor on drug-resistant tumors and other hard-to-treat cancers. Yu said Navire...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...Recursion Pharmaceuticals Inc. hired Shafique Virani as chief corporate development officer. He was CEO of Navire Pharma Inc....
BioCentury | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

...Oxford BioMedica plc (LSE:OXB). Virani was CEO-in-residence at BridgeBio Pharma Inc. (NASDAQ:BBIO) and CEO of Navire Pharma Inc....
BioCentury | Aug 17, 2018
Finance

MD Anderson’s blooms

...cited the 2017 launches of autophagy company Vescor LLC with Deerfield Management and cancer subsidiary Navire Pharma Inc....
...autophagy-targeted cancer, and the newco will own the rights to all developed candidates. With BridgeBio, Navire...
BioCentury | Nov 9, 2017
Finance

The return of big

...since the start of 4Q17. One was with BridgeBio Pharma LLC to create the JV Navire Pharma Inc....
...of Biomedical Innovation Health and Nutrition, Osaka, Japan National Institutes of Health (NIH), Bethesda, Md. Navire Pharma Inc....
BioCentury | Oct 6, 2017
Company News

BridgeBio launches SHP-2 inhibitor play Navire

...BridgeBio Pharma LLC (Palo Alto, Calif.) launched Navire Pharma Inc. , a subsidiary aimed at treating genetically driven...
...a subsidiary aimed at treating genetically driven, treatment-resistant cancer, with a $30 million investment. Navire...
...led by IACS' Phil Jones and New York University's Benjamin Neel discovered Navire's lead compounds. Navire’s...
Items per page:
1 - 10 of 11